Adi Raviv Continues as Chief Executive Officer and President
LUTZ, FL / ACCESSWIRE / January 27, 2022 / Mirror Biologics, Inc. ("Mirror Biologics", the "Company"), is a clinical-stage immunotherapy company pioneering the development, manufacturing, future commercialization, and clinical translation of next-generation immunomodulatory and therapeutic in-situ vaccines for cancer and infectious diseases. Today, Mirror Biologics announced the election of Mr. Joel Kanter as the new Chairman of the board of directors. Mr. Kanter succeeds Adi Raviv who served as the Interim Chairman since mid-2021. Mr. Raviv will continue as Chief Executive Officer and President of Mirror Biologics while remaining a member of the board of directors.
Joel Kanter has been involved in providing venture capital financing to early-stage, healthcare companies for more than 35 years. Mr. Kanter stated, "For us to have a significant impact on dramatically extending life expectancy and reducing healthcare expenditures, we simply have to find better solutions to the harrowing impact cancer has on its patients. Mirror Biologics' innovative approach to treatment, which will be evaluated for efficacy across the oncology spectrum, can potentially alter the impact of a disease that currently afflicts almost 20 million people annually and kills over 10 million. It is a privilege to be a part of Mirror Biologics as it works to achieve its objectives to extend the lives of patients with cancer with quality of life."
"I join with my fellow board members, Company management and team members, shareholders and all other valued stakeholders in extending a warm welcome to our new Chairman of the Board, Joel Kanter," said Adi Raviv. "I am very confident that under Joel's leadership, the Mirror Biologics' board and its distinguished members will continue to make a valuable contribution in furthering the efforts of our Company to achieve our primary mission - to transform the approach to cancer treatment with therapeutic vaccinations. Mirror Biologics seeks to commercialize our experimental drug AlloStim®, the active, off-the-shelf, living-immune cell vaccine component currently in development. AlloStim is designed with the objective of creating a new generation of allogeneic, disease agnostic, cost-effective, widely available, and minimally-toxic therapeutic vaccines against all types of cancer and viral infections."
About Mirror Biologics, Inc.
Mirror Biologics, Inc. ("Mirror Biologics", the "Company") is a clinical-stage, immunotherapy company pioneering the development, manufacturing, future commercialization, and clinical translation of next- generation immunomodulatory and therapeutic in-situ vaccines for cancer and infectious diseases. Mirror Biologics, founded in 2019, is an international biopharmaceutical company headquartered near Tampa, Florida with locations in Israel and Asia. The Company conducts advanced bioengineering research and development and is establishing a 21 CFR 1271-compliant blood donor and cell processing center as well as a medical facility for the treatment of patients pursuant to FDA guidelines such as Expanded Access and Right to Try provisions. Mirror Biologics operates a GMP cell manufacturing facility in Jerusalem, Israel and has clinical and distribution partner offices in Bangkok, Thailand and Kuala Lumpur, Malaysia. The lead experimental drug, AlloStim®, is an "off-the-shelf", non-genetically manipulated, patented, living immune cell differentiated from precursor cells purified from the blood of healthy donors and formulated with monoclonal antibody-coated microparticles. Proprietary "artificial lymph node" bioreactors are being developed and are expected to enable the economical high-cell density scale-up of AlloStim. The Mirror Effect® technology platform and related applications are protected by over 200 patents worldwide.
For more information on Mirror Biologics, please visit:
Website: www.mirrorbio.com
LinkedIn: https://www.linkedin.com/company/mirror-biologics-inc
Forward-Looking Statements
The information contained herein may contain "forward‐looking statements". Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Mirror Biologics concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.
Corporate Contact:
Adi Raviv
Chief Executive Officer
Mirror Biologics, Inc.
2550 Green Forest Lane, Suite 100
Lutz, Florida 33558
Email: [email protected]
Investor Contact:
Jennifer K. Zimmons, PhD, MBA
Investor Relations
Zimmons International Communications, Inc.
Phone: +1.917.214.3514
E-mail: [email protected]
SOURCE: Mirror Biologics, Inc.